Skip to main content

Table 3 Descriptive analysis for clinical and biological manifestations potentially related to HHV-6 reactivation

From: Human herpesvirus-6 in hematopoietic stem cell transplant recipients: a prospective cohort study in Egypt

 

Patients negative for HHV-6 DNAemia

(n = 25)

Patients positive for HHV-6 DNAemia

(n = 15)

No

%

No

%

Asymptomatic

6

24.0

2

13.3

Unexplained fever

13

52.0

6

40.0

Cutaneous rash

0

0.0

2

13.3

Pneumonitis

2

8.0

2

13.3

aGVHD

0

0.0

1

6.7

Encephalitis

0

0.0

0

0.0

Thrombocytopenia

2

8.0

5

33.3

Delayed engraftment/bone marrow suppression

4

16.0

6

40.0

Days to platelets engraftment

    

 Min.–Max

5.0–22.0

 

8.0–13.0

 

 Mean ± SD

12.16 ± 3.14

 

10.80 ± 1.61

 

 Median (IQR)

12.0 (11.0–14.0)

 

11.0 (10.0–12.0)

 

Days to neutrophils engraftment

    

 Min.–Max

7.0–24.0

 

9.0–28.0

 

 Mean ± SD

12.84 ± 3.06

 

13.80 ± 5.16

 

 Median (IQR)

12.0 (11.0–13.0)

 

12.0 (10.0–15.50)

 
  1. HHV-6 human herpes virus-6, aGVHD acute graft versus host disease